PearlMatrix™ Hits the OR: First U.S. Patient Post-FDA Approval

The champagne corks are probably still rolling around at Cerapedics HQ. In June 2025, the company secured FDA premarket approval for its PearlMatrix™ P-15 Peptide Enhanced Bone Graft — and now they’ve marked another milestone: the first U.S. patient treated post-approval.

Approved for single-level transforaminal lumbar interbody fusion (TLIF) in adults with degenerative disc disease, PearlMatrix isn’t just another bone graft — Cerapedics says it’s the first and only bone growth accelerator proven to speed lumbar fusion, showing statistically superior fusion rates in single-level TLIF procedures.